PL1541197T3 - Zastosowanie pipamperonu i SNDRI, SNRI lub SSRI do leczenia zaburzeń nastroju lub zaburzeń lękowych z niepokojem - Google Patents
Zastosowanie pipamperonu i SNDRI, SNRI lub SSRI do leczenia zaburzeń nastroju lub zaburzeń lękowych z niepokojemInfo
- Publication number
- PL1541197T3 PL1541197T3 PL04025035T PL04025035T PL1541197T3 PL 1541197 T3 PL1541197 T3 PL 1541197T3 PL 04025035 T PL04025035 T PL 04025035T PL 04025035 T PL04025035 T PL 04025035T PL 1541197 T3 PL1541197 T3 PL 1541197T3
- Authority
- PL
- Poland
- Prior art keywords
- compounds
- agonistic
- antagonistic
- treatment
- inverse
- Prior art date
Links
- 208000019901 Anxiety disease Diseases 0.000 title 1
- 208000019022 Mood disease Diseases 0.000 title 1
- 230000036651 mood Effects 0.000 title 1
- AXKPFOAXAHJUAG-UHFFFAOYSA-N pipamperone Chemical compound C1CC(C(=O)N)(N2CCCCC2)CCN1CCCC(=O)C1=CC=C(F)C=C1 AXKPFOAXAHJUAG-UHFFFAOYSA-N 0.000 title 1
- 229960002776 pipamperone Drugs 0.000 title 1
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 title 1
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 title 1
- 239000003775 serotonin noradrenalin reuptake inhibitor Substances 0.000 title 1
- 239000003174 triple reuptake inhibitor Substances 0.000 title 1
- 230000001270 agonistic effect Effects 0.000 abstract 8
- 150000001875 compounds Chemical class 0.000 abstract 8
- 230000003042 antagnostic effect Effects 0.000 abstract 4
- 102100036321 5-hydroxytryptamine receptor 2A Human genes 0.000 abstract 3
- 101710138091 5-hydroxytryptamine receptor 2A Proteins 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 2
- 239000000126 substance Substances 0.000 abstract 2
- 208000035154 Hyperesthesia Diseases 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000008482 dysregulation Effects 0.000 abstract 1
- 230000002996 emotional effect Effects 0.000 abstract 1
- 230000009610 hypersensitivity Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03447279A EP1547650A1 (en) | 2003-12-02 | 2003-12-02 | Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
| EP04447001 | 2004-01-05 | ||
| EP04447066A EP1576985A1 (en) | 2004-03-18 | 2004-03-18 | Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
| EP04025035A EP1541197B8 (en) | 2003-12-02 | 2004-10-21 | Use of pipamperone and an SNDRI, SNRI or SSRI for the treatment of mood or anxiety disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1541197T3 true PL1541197T3 (pl) | 2009-10-30 |
Family
ID=40490565
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL04025035T PL1541197T3 (pl) | 2003-12-02 | 2004-10-21 | Zastosowanie pipamperonu i SNDRI, SNRI lub SSRI do leczenia zaburzeń nastroju lub zaburzeń lękowych z niepokojem |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1541197B8 (pl) |
| JP (1) | JP4571485B2 (pl) |
| AT (1) | ATE425752T1 (pl) |
| CY (1) | CY1110316T1 (pl) |
| DE (1) | DE602004020042D1 (pl) |
| DK (1) | DK1541197T3 (pl) |
| ES (1) | ES2323269T3 (pl) |
| PL (1) | PL1541197T3 (pl) |
| PT (1) | PT1541197E (pl) |
| SI (1) | SI1541197T1 (pl) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7094572B2 (en) | 2003-03-14 | 2006-08-22 | Bristol-Myers Squibb | Polynucleotide encoding a novel human G-protein coupled receptor variant of HM74, HGPRBMY74 |
| US7855195B2 (en) | 2003-12-02 | 2010-12-21 | Pharmaneuroboost N.V. | Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
| JP4571645B2 (ja) * | 2003-12-02 | 2010-10-27 | ファルマニューロブースト エン．フェー． | Ｄ４および５−ｈｔ２ａアンタゴニスト、逆アゴニストまたは部分アゴニストの使用 |
| GB0417702D0 (en) * | 2004-08-09 | 2004-09-08 | Merck Sharp & Dohme | New uses |
| KR20070059079A (ko) * | 2004-09-03 | 2007-06-11 | 다이니뽄 스미토모 세이야쿠 가부시키가이샤 | 경피 페로스피론 투여용 의약적 조성물 |
| WO2006083204A1 (en) * | 2004-12-27 | 2006-08-10 | Alpha 2 Pharmaceutical Ab | Antidepressant medicament comprising idazoxan and a selective serotonin reuptake inhibitor |
| TW200800959A (en) | 2005-06-10 | 2008-01-01 | Wyeth Corp | Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor |
| EP2258357A3 (en) * | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
| WO2007146073A2 (en) * | 2006-06-09 | 2007-12-21 | Wyeth | Method for enhancing cognitive function |
| WO2008030651A1 (en) * | 2006-09-08 | 2008-03-13 | Braincells, Inc. | Combinations containing a 4-acylaminopyridine derivative |
| EP2337564A1 (en) * | 2008-09-04 | 2011-06-29 | NeuroSearch A/S | A method for combating adverse effects arising from antipsychotic treatment |
| US8198268B2 (en) | 2008-10-31 | 2012-06-12 | Janssen Biotech, Inc. | Tianeptine sulfate salt forms and methods of making and using the same |
| EP2236138A1 (en) * | 2009-03-30 | 2010-10-06 | PharmaNeuroBoost N.V. | Low dose pipamperone in treating mood and anxiety disorders |
| WO2011069075A2 (en) * | 2009-12-04 | 2011-06-09 | Grant Jon E | Treating impulse control disorders with catechol-o- methyl-transferase inhibitors |
| WO2021139874A1 (en) * | 2020-01-06 | 2021-07-15 | Anima | Cognitive disorder prevention and therapy |
| CN113181183A (zh) * | 2021-05-20 | 2021-07-30 | 桂林医学院 | 卡麦角林在制备治疗焦虑障碍的药物组合物中的应用 |
| CN114797036B (zh) * | 2022-06-27 | 2022-09-27 | 深圳市心流科技有限公司 | 一种专注力训练方案制定方法、装置、设备及存储介质 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4039631A1 (de) * | 1990-12-12 | 1992-06-17 | Troponwerke Gmbh & Co Kg | Neuroprotektive kombination |
| US5554383A (en) * | 1995-04-06 | 1996-09-10 | Trustees Of Tufts College | Veterinary method for clinically modifying the behavior of dogs exhibiting canine affective aggression |
| TW587938B (en) * | 1997-03-27 | 2004-05-21 | Akzo Nobel Nv | Pharmaceutical composition for the treatment and/or prophylaxis of psychotic disorder |
| JP4571645B2 (ja) * | 2003-12-02 | 2010-10-27 | ファルマニューロブースト エン．フェー． | Ｄ４および５−ｈｔ２ａアンタゴニスト、逆アゴニストまたは部分アゴニストの使用 |
-
2004
- 2004-10-21 DK DK04025035T patent/DK1541197T3/da active
- 2004-10-21 PL PL04025035T patent/PL1541197T3/pl unknown
- 2004-10-21 PT PT04025035T patent/PT1541197E/pt unknown
- 2004-10-21 AT AT04025035T patent/ATE425752T1/de active
- 2004-10-21 EP EP04025035A patent/EP1541197B8/en not_active Expired - Lifetime
- 2004-10-21 DE DE602004020042T patent/DE602004020042D1/de not_active Expired - Lifetime
- 2004-10-21 SI SI200431110T patent/SI1541197T1/sl unknown
- 2004-10-21 ES ES04025035T patent/ES2323269T3/es not_active Expired - Lifetime
- 2004-11-04 JP JP2004349085A patent/JP4571485B2/ja not_active Expired - Fee Related
-
2009
- 2009-05-19 CY CY20091100533T patent/CY1110316T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2323269T3 (es) | 2009-07-10 |
| JP2005194263A (ja) | 2005-07-21 |
| EP1541197A1 (en) | 2005-06-15 |
| JP4571485B2 (ja) | 2010-10-27 |
| EP1541197B1 (en) | 2009-03-18 |
| SI1541197T1 (sl) | 2009-08-31 |
| PT1541197E (pt) | 2009-06-04 |
| ATE425752T1 (de) | 2009-04-15 |
| DK1541197T3 (da) | 2009-06-15 |
| DE602004020042D1 (de) | 2009-04-30 |
| EP1541197B8 (en) | 2009-06-10 |
| CY1110316T1 (el) | 2015-01-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1110316T1 (el) | Χρηση πιπαμπερονης και ενος sndri, snri ή ssri για την θεραπεια διαταραχων ψυχικης διαθεσης ή αγχους | |
| NO20071560L (no) | Vasopressin v1a-antagonister. | |
| TW200503674A (en) | Therapeutic agents | |
| IL196543A (en) | Pyridazinone derivatives, pharmaceutical preparations containing them for use in the treatment of disorders | |
| DE60325379D1 (de) | Zusammensetzung enthaltend 6-Ä3-(1-adamantyl)-4-methoxyphenylÜ-2-naphthanoesäure zur Behandlung dermatologischer Erkrankungen | |
| ATE442142T1 (de) | Fredericamycin-derivate als arzneimittel zur tumorbehandlung | |
| IL188942A0 (en) | Benzimidazole derivatives and pharmaceutical compositions containing the same | |
| ATE517861T1 (de) | Benzylether und benzylaminoverbindungen als inhibitoren von beta-secretase zur behandlung von alzheimer-krankheit | |
| EA200601212A1 (ru) | Ингибиторы фосфодиэстеразы, получение и их терапевтическое применение | |
| ATE479655T1 (de) | Neue aminoazetidin-, aminopyrrolidin- und aminopiperidinderivative | |
| CY1109366T1 (el) | Υποκατεστημενες ενωσεις 1,4,8-τριαζασπειρο[4.5]δεκαν-2-ονης | |
| ATE181329T1 (de) | Substituierte dibenzooxazepin-verbindungen, pharmazeutische zusammensetzungen und verfahren zur verwendung | |
| EA200601846A1 (ru) | Содержащие бензоксазины лекарственные комбинации для лечения заболеваний дыхательных путей | |
| DE502005008058D1 (de) | Gesättigte und ungesättigte 3-pyridyl-benzocycloalkylmethyl-amine zur behandlung von schmerzen, depressionen und angstzuständen | |
| DE502005008971D1 (de) | Substituierte 1,4,8-triazaspiroä4.5 decan-2-on-verbindungen zur behandlung von fettsucht | |
| TW200716529A (en) | New compounds II | |
| EA200900269A1 (ru) | Лекарственные комбинации для лечения заболеваний дыхательных путей | |
| WO2004042389A3 (en) | Diagnostics and therapeutics for diseases associated with human phosphodiesterase 4d (pde4d) | |
| MY146802A (en) | Novel drugs for treating respiratory diseases | |
| ATE554393T1 (de) | Diagnostika und therapeutika für mit adiponectin receptor 2 (adipor2) assoziierten erkrankungen | |
| UY29078A1 (es) | Amidas del ácido 5 y 6-aminoalquil indol-2-carboxílico 3-sustituidas y análogos relacionados como inhibidores de la caseína cinasa ie(epsilon) | |
| ATE391710T1 (de) | Substituierte azetidinverbindungen als cyclooxigenase-1-cyclooxygenase-2-inhibitoren und deren herstellung und verwendung als medikament | |
| CY1111017T1 (el) | Χρηση πιπαμπερονης και ενος ανταγωνιστη d-2 υποδοχεα ή ανταγωνιστη σεροτονινης/ντοπαμινης για την θεραπεια ψυχωτικων διαταραχων | |
| DE10390702D2 (de) | 2-Methylthiazolidin-2,4-Dicarbonsäure und deren Salze zur Behandlung von neurodegenerativen Erkrankungen | |
| DE602004028113D1 (de) | Verwendung von 2,3-Dehydronaringenin-Derivaten zur Behandlung von Entzündungsprozessen und diese Derivate enthaltende pharmazeutische Zusammensetzung |